Semaglutide Treatment On Coronary Progression

NCT03985384 · clinicaltrials.gov ↗

PHASE4

Phase

COMPLETED

Status

140

Enrollment

OTHER

Sponsor class

Conditions

Type 2 Diabetes
Coronary Artery Disease

Interventions

DRUG: Semaglutide 2 MG/1.5 ML Subcutaneous Solution
DRUG: Placebo

Sponsor

Lundquist Institute for Biomedical Innovation at Harbor-UCLA Medical Center